دورية أكاديمية
Organokines and liver enzymes in adolescent girls with polycystic ovary syndrome during randomized treatments.
| العنوان: | Organokines and liver enzymes in adolescent girls with polycystic ovary syndrome during randomized treatments. |
|---|---|
| المؤلفون: | Garcia-Beltran C; Endocrinology Department, Institut de Recerca Sant Joan de Déu, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain., Peyrou M; Biochemistry and Molecular Biomedicine Department, Biomedicine Institute, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain., Navarro-Gascon A; Biochemistry and Molecular Biomedicine Department, Biomedicine Institute, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain., López-Bermejo A; Pediatric Endocrinology Research Group, Girona Institute for Biomedical Research (IDIBGI), Faculty of Medicine, University of Girona and Dr. Josep Trueta Hospital, Girona, Spain., de Zegher F; Leuven Research and Development, University of Leuven, Leuven, Belgium., Villarroya F; Biochemistry and Molecular Biomedicine Department, Biomedicine Institute, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain., Ibáñez L; Endocrinology Department, Institut de Recerca Sant Joan de Déu, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. |
| المصدر: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 May 16; Vol. 15, pp. 1325230. Date of Electronic Publication: 2024 May 16 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Polycystic Ovary Syndrome*/drug therapy , Polycystic Ovary Syndrome*/metabolism , Polycystic Ovary Syndrome*/blood , Metformin*/therapeutic use , Fibroblast Growth Factors*/blood , Fibroblast Growth Factors*/metabolism , Liver*/drug effects , Liver*/metabolism , Alanine Transaminase*/blood , Alanine Transaminase*/metabolism, Humans ; Female ; Adolescent ; Pioglitazone/therapeutic use ; Biomarkers/blood ; Spironolactone/therapeutic use ; Aspartate Aminotransferases/blood ; Aspartate Aminotransferases/metabolism ; gamma-Glutamyltransferase/blood ; gamma-Glutamyltransferase/metabolism ; Non-alcoholic Fatty Liver Disease/drug therapy ; Non-alcoholic Fatty Liver Disease/metabolism ; Contraceptives, Oral/adverse effects ; Contraceptives, Oral/therapeutic use ; Contraceptives, Oral/administration & dosage ; Hypoglycemic Agents/therapeutic use |
| مستخلص: | Introduction: Polycystic ovary syndrome (PCOS) is often associated with metabolic-associated fatty liver disease (MAFLD). MAFLD has been associated with altered hepatic function, systemic dysmetabolism, and abnormal circulating levels of signaling molecules called organokines. Here, we assessed the effects of two randomized treatments on a set of organokines in adolescent girls with PCOS and without obesity, and report the associations with circulating biomarkers of liver damage, which were assessed longitudinally in the aforementioned studies as safety markers. Materials and Methods: Liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT)] were assessed as safety markers in previous randomized pilot studies comparing the effects of an oral contraceptive (OC) with those of a low-dose combination of spironolactone-pioglitazone-metformin (spiomet) for 1 year. As a post hoc endpoint, the organokines fibroblast growth factor-21 (FGF21), diazepam-binding protein-1 (DBI), and meteorin-like protein (METRNL) were assessed by ELISA after 6 months of OC (N = 26) or spiomet (N = 28). Auxological, endocrine-metabolic, body composition (using DXA), and abdominal fat partitioning (using MRI) were also evaluated. Healthy, age-matched adolescent girls (N = 17) served as controls. Results: Circulating ALT and GGT levels increased during OC treatment and returned to baseline concentrations in the post-treatment phase; in contrast, spiomet treatment elicited no detectable changes in ALT and GGT concentrations. In relation to organokines after 6 months of treatment, (1) FGF21 levels were significantly higher in PCOS adolescents than in control girls; (2) DBI levels were lower in OC-treated girls than in controls and spiomet-treated girls; and (3) no differences were observed in METRNL concentrations between PCOS girls and controls. Serum ALT and GGT levels were directly correlated with circulating METRNL levels only in OC-treated girls (R = 0.449, P = 0.036 and R = 0.552, P = 0.004, respectively). Conclusion: The on-treatment increase in ALT and GGT levels occurring only in OC-treated girls is associated with circulating METRNL levels, suggesting enhanced METRNL synthesis as a reaction to the hepatic changes elicited by OC treatment. Clinical Trial Registration: https://doi.org, identifiers 10.1186/ISRCTN29234515, 10.1186/ISRCTN11062950. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Garcia-Beltran, Peyrou, Navarro-Gascon, López-Bermejo, de Zegher, Villarroya and Ibáñez.) |
| References: | J Clin Endocrinol Metab. 2023 Dec 21;109(1):10-24. (PMID: 37329216) J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447-2469. (PMID: 37580314) Front Genet. 2021 Feb 02;12:598855. (PMID: 33603771) J Clin Med. 2023 Jan 20;12(3):. (PMID: 36769504) Sci Rep. 2021 Mar 29;11(1):7018. (PMID: 33782413) J Endocr Soc. 2020 Mar 14;4(5):bvaa032. (PMID: 32342022) Cell Metab. 2023 Feb 7;35(2):236-252. (PMID: 36754018) Int J Environ Res Public Health. 2018 Nov 20;15(11):. (PMID: 30463276) Trends Mol Med. 2023 May;29(5):354-363. (PMID: 36964058) J Clin Endocrinol Metab. 2022 Jan 1;107(1):258-272. (PMID: 34491336) J Adolesc Health. 2017 Oct;61(4):446-453. (PMID: 28712591) Eur J Endocrinol. 2023 Jul 20;189(1):S1-S16. (PMID: 37440702) Autophagy. 2023 May;19(5):1604-1606. (PMID: 36198092) Exp Clin Endocrinol Diabetes. 2022 Jun;130(6):406-414. (PMID: 34407548) Endocr Rev. 2019 Oct 1;40(5):1367-1393. (PMID: 31098621) Adv Clin Chem. 2020;94:261-321. (PMID: 31952573) Clin Endocrinol (Oxf). 2019 Mar;90(3):425-432. (PMID: 30548504) Diabetes Metab. 2016 Jun;42(3):196-9. (PMID: 26546387) BMC Med. 2023 Feb 20;21(1):62. (PMID: 36800955) Biomedicines. 2022 Jan 07;10(1):. (PMID: 35052811) Front Endocrinol (Lausanne). 2023 Mar 02;14:1136245. (PMID: 36936161) Horm Res Paediatr. 2017;88(6):371-395. (PMID: 29156452) Cell. 2014 Jun 5;157(6):1279-1291. (PMID: 24906147) Clin Chim Acta. 2021 Oct;521:19-24. (PMID: 34153276) Int J Endocrinol. 2018 Jul 19;2018:4192940. (PMID: 30123261) Int J Clin Pract. 2008 Sep;62(9):1337-43. (PMID: 18565127) Best Pract Res Clin Endocrinol Metab. 2013 Feb;27(1):13-24. (PMID: 23384742) Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2207344119. (PMID: 36191214) Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):387-388. (PMID: 32461575) Front Endocrinol (Lausanne). 2021 Nov 29;12:795520. (PMID: 34912302) Nat Med. 2012 Aug;18(8):1279-85. (PMID: 22842477) Fertil Steril. 2021 Jun;115(6):1569-1575. (PMID: 33509630) Front Cardiovasc Med. 2023 Apr 26;10:1119005. (PMID: 37180779) Metabolism. 2019 Dec;101:153994. (PMID: 31672443) BMJ Open Gastroenterol. 2021 May;8(1):. (PMID: 34011622) Clin Endocrinol (Oxf). 2023 Jul;99(1):79-91. (PMID: 36939017) Pediatr Obes. 2021 Nov;16(11):e12802. (PMID: 34014038) J Clin Lab Anal. 2018 Jan;32(1):. (PMID: 28276605) Toxicology. 2008 Mar 20;245(3):194-205. (PMID: 18291570) BMJ Open Diabetes Res Care. 2020 Feb;8(1):. (PMID: 32107266) Dis Markers. 2015;2015:818570. (PMID: 26543300) Front Immunol. 2023 Feb 24;14:1098570. (PMID: 36911663) Diabetes Obes Metab. 2019 Mar;21(3):509-516. (PMID: 30225967) Int J Obes (Lond). 2018 Apr;42(4):919-922. (PMID: 29081506) Science. 2022 Jun 17;376(6599):1343-1347. (PMID: 35709278) Metabolism. 2022 May;130:155179. (PMID: 35283187) |
| فهرسة مساهمة: | Keywords: METRNL; PCOS; liver enzymes; metformin; oral contraceptives; organokines; pioglitazone; spironolactone |
| المشرفين على المادة: | 9100L32L2N (Metformin) 62031-54-3 (Fibroblast Growth Factors) EC 2.6.1.2 (Alanine Transaminase) X4OV71U42S (Pioglitazone) 0 (Biomarkers) 27O7W4T232 (Spironolactone) EC 2.6.1.1 (Aspartate Aminotransferases) EC 2.3.2.2 (gamma-Glutamyltransferase) 0 (Contraceptives, Oral) 0 (FGF21 protein, human) 0 (Hypoglycemic Agents) |
| تواريخ الأحداث: | Date Created: 20240531 Date Completed: 20240531 Latest Revision: 20240626 |
| رمز التحديث: | 20240627 |
| مُعرف محوري في PubMed: | PMC11137167 |
| DOI: | 10.3389/fendo.2024.1325230 |
| PMID: | 38818508 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!